A Phase 1/2/3 Study of UX701 Gene Therapy in Adults With Wilson Disease
Key facts
- Who runs it
- Ultragenyx Pharmaceutical Inc
- Where
- Ann Arbor, Boston, Chicago, Cleveland, Durham, Indianapolis, Los Angeles, Nashville, Redwood City, Sacramento, Salt Lake City, and Seattle, United StatesSee the 12 sitesAlso in 6 other countries, 9 sites
- Status
- Active, not recruiting
- Phase
- Phase 1/2
- People taking part
- 82 people, planned
- Started
- 27 Sept 2021
- Expected to end
- Mar 2034
- Type of study
- Interventional, 6 groups
- Treatments tested
- UX701
- Standard of Care (SOC)
- Record updated
- 25 September 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Confirmed diagnosis of Wilson disease based on genetic confirmation of heterozygous or homozygous biallelic ATP7B mutation
- Stable Wilson disease as evidenced by ongoing copper chelator (ie, penicillamine, trientine) and/or zinc therapy for at least 2 months at screening, with no medication or dose changes for at least 2 months at screening
- Ongoing restriction of high copper containing foods for at least 2 months at Screening and continued through study participation
- Willing and able to comply with all study procedures and requirements, including frequent blood collection, total urine collection over a 24-hour period, patient-reported outcome assessments, and long-term follow-up
Who cannot take part
- Detectable pre-existing antibodies to the AAV9 capsid
- Stage 1 only: History of copper chelator or zinc therapy noncompliance, in the Investigator's judgment, within 6 months prior to Screening
- History of liver transplant
- Active decompensated hepatic cirrhosis or history of hepatic encephalopathy
- Model for End-Stage Liver Disease (MELD) score > 13
- Presence of Stage 3 or higher chronic kidney disease based on estimated glomerular filtration rate < 60 mL/min/1.73 m2
- Moderate to severe depression, recent or active suicidal ideation with intent or suicidal behavior, psychosis, or unstable psychiatric illness
- Known hypersensitivity to UX701 or its excipients, copper chelators, zinc, rituximab, tacrolimus, corticosteroids, or eculizumab that, in the Investigator's judgement, places the participant at increased risk for adverse events
- Subjects with known hypersensitivity to amide-containing local anesthetics are excluded from participating in the optional liver biopsy substudy; Note: Other protocol defined Inclusion/ Exclusion criteria may apply
- Significant hepatic inflammation as evidenced by laboratory abnormalities
- Hemoglobin < 9 g/dL
- Marked neurological deficit or compromise that, in the Investigator's opinion, would interfere with the subject's safety or ability to participate in the study
- Participation in another gene transfer study or use of another gene transfer product before or during study participation
Where in United States
Also in 6 other countries, 9 sites
- University of MichiganAnn Arbor, United States
- Massachusetts General HospitalBoston, United States
- Northwestern UniversityChicago, United States
- University Hospitals Cleveland Medical Center*Cleveland, United States
- Duke University Medical CenterDurham, United States
- Indiana UniversityIndianapolis, United States
- University of California, Los AngelesLos Angeles, United States
- Vanderbilt University Medical CenterNashville, United States
- Stanford UniversityRedwood City, United States
- University of California - DavisSacramento, United States
- University of UtahSalt Lake City, United States
- Seattle Children's HospitalSeattle, United States
About the trial
What the trial wants to find out
The primary objectives of this study are to evaluate the safety of single IV doses of UX701 in patients with Wilson disease, to select the UX701 dose with the best benefit/risk profile based on the totality of safety and efficacy data and to evaluate the effect of UX701 on copper regulation.
The 6 groups in the trial
- Stage 1: UX701 Dose Level 1Treatment being tested
Participants receive a single, peripheral intravenous (IV) infusion of UX701 at dose level 1.
Treatment: UX701
- Stage 1: UX701 Dose Level 2Treatment being tested
Participants receive a single, peripheral IV infusion of UX701 at dose level 2.
Treatment: UX701
- Stage 1: UX701 Dose Level 3Treatment being tested
Participants receive a single, peripheral IV infusion of UX701 at dose level 3.
Treatment: UX701
- Stage 1: UX701 Dose Level 4Treatment being tested
Participants receive a single, peripheral IV infusion of UX701 at dose level 4.
Treatment: UX701
- Stage 2: UX701 at Selected DoseTreatment being tested
Participants randomized to UX701 receive a single, peripheral IV infusion of UX701 at the selected dose.
Treatment: UX701
- Stage 2: Standard of Care (SOC) to UX701Treatment being tested
Participants randomized to SOC will continue their baseline SOC medications for 52 weeks, followed by a single, peripheral IV infusion of UX701 at the selected dose. Following UX701 administration, participants will be evaluated for modification of their SOC medications.
Treatment: UX701 and Standard of Care (SOC)
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- An Operationally Seamless Phase 1/2/3 Study Consisting of a Safety and Dose-finding Phase 1/2 and Randomized, Open-label, Active-controlled Phase 3 to Evaluate UX701 AAV Gene Therapy in Adults With Wilson Disease
- Record updated
- 25 September 2026